Prevalence of diabetes in Poland in the years 2010–2014 by Walicka, Magdalena et al.
 ORIGINAL ARTICLE ISSN 2084–4441
232 www.dk.viamedica.pl
Magdalena Walicka1, Marcin Chlebus2, Melania Brzozowska3,  
Andrzej Śliwczyński3, 4, Tadeusz Jędrzejczyk3, Lidia Kania1, 5,  
Monika Puzianowska-Kuźnicka5, 6, Edward Franek1, 5 
1Department of Internal Diseases, Endocrynology and Diabetology of the Central Clinical Hospital of the Ministry  
of the Interior in Warsaw  
2Department of Quantitative Finance, Faculty of Economic Sciences, Warsaw University  
3National Health Fund  
4Public Health Department, Faculty of Health Science of the Medical University in Łódź 
5Clinical-Research Complex of Human Epigenetics Institute of Experimental and Clinical Medicine named after M. Mossakowski PAN in Warsaw 
6Institute of Gerontology and Geriatrics Postgraduate Education Medical Center Warsaw
Prevalence of diabetes in Poland  
in the years 2010–2014 
ABSTRACT
Introduction. Each year diabetes affects larger and 
larger number of people. Despite this fact, the num-
ber of people suffering from diabetes in Poland is not 
known precisely. In order to assess this prevalence, 
the thesis aims at assessing the prevalence of diabetes 
in the years 2010–2014 in the total Polish population 
by using the databases of the National Health Fund.
Material and methods. In the period from 1st January 
2010 until 31st December 2014 patients were distin-
guished according to PESEL (Personal Identification) 
numbers: 1. for whom health care providers have indi-
cated diabetes-related ICD-10 codes as the main cause 
of the medical intervention in billing reports; 2. who 
had got their prescriptions filled for any hypoglycemic 
agents or for glucose meter test strips. The number of 
patients recorded as diabetes patients according to 
the ICD-10 code and the number of patients who had 
their prescriptions filled for hypoglycemic agents or 
test strips were assessed. On the basis of these data 
the prevalence of diabetes (percentage of people with 
diabetes in a given year or a percentage of people who 
had got their prescriptions filled for hypoglycemic 
agents or test strips in relation to the general popula-
tion) in respective years and an average prevalence rate 
for respective voivodeships were assessed.
Results. The average percentage of people with dia-
betes in the years 2010–2014 were found to be 4.47% 
(± 0.09%). This percentage has gradually increased in 
the consecutive years from 4.39% in 2010 to 4.61% in 
2014. The average percentage of people who had got 
their prescriptions filled for diabetes related medi-
cines or glucose meter test strips amounted to 5.88% 
in the years 2010–2014. The largest percentage of 
people with diabetes was in Silesian Voivodeship and 
amounted to 5.5% (± 0.1%), the second consecutive 
voivodeship was Łódź with 5.0% (± 0.2%) of people 
with diabetes and Opole Voivodeship on the third place 
with 4.9% (0.1%) inhabitants with diabetes. The small-
est percentage of people with diabetes was noted in 
Warmian-Masurian Voivodeship — 3.5% (± 0.1%) and 
Subcarpathian Voivodeship — 3.6% (± 0.2%).
Conclusions. 1. Average diabetes prevalence rate in 
Poland in the years 2010–2014 amounted to 4.47% (the 
assessment was carried out on the basis of the number 
of people recorded by the National Health Fund as 
patients with diabetes) or 5.88% (assessment on the 
basis of the number of people who got their prescrip-
tions filled for reimbursable hypoglycemic agents or 
glucose meter test strips). 2. Diabetes prevalence in 
Poland increases in the consecutive years. 3. Prevalence 
of diabetes varies among voivodeships. (Clin Diabet 
2015; 4, 6: 232–237)
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Introduction
Due to an unhealthy lifestyle, too little physical 
activity and the increase of cases of overweight and 
obesity, prevalence of diabetes increases at an alarm-
ing rate in all regions of the world [1, 2]. According to 
the IDF (International Diabetes Federation) data, there 
were 387 million people with diabetes in the world in 
2014 and this disease has not been diagnosed among 
more than 46% of these people [3]. The World Health 
Organization (WHO) points to diabetes as one of the 
most serious threats of this century. It is the first and 
so far the only non-infectious disease which has been 
recognized by the United Nations as the epidemic of 
the 21st century [4].
The mortality of people with diabetes is higher and 
their expected survival is shorter in comparison with 
people not affected by diabetes [5]. WHO predicts that 
in 2030 diabetes will be the seventh leading cause of 
death worldwide [6].
Diabetes also involves considerable financial bur-
dens on the state budget. In 2013 about 2.5 billion PLN 
was spent in Poland for the treatment of this disease 
(in comparison with 2012, the expenditures increased 
by 3.6%) [7]. 
Due to the exponential increase of people with 
diabetes, it is necessary to provide a high quality of 
a well organized diabetes care. In order to plan these 
actions it is necessary to possess knowledge about the 
scale of the problem in our country. Unfortunately, 
the number of people with diabetes in Poland is not 
precisely known because we do not have a national 
register of people suffering from this disease. The avail-
able data concerning diabetes epidemiology in Poland 
derive from research which was carried out by means 
of different selection criteria on groups of patients in 
different age brackets with different types of diabetes, 
in separate cities or regions [9–17]. Studies were also 
carried out on representative samples of the Polish 
population, however, they also have their limits. For 
example, no blood glucose concentration curves were 
carried out in any of these studies, in NATPOL studies 
the population from the age of 18 was assessed and 
in the POLSENIOR and WOBASZ studies the population 
was limited to older people [18–21]. That is why this 
thesis aims at assessing the prevalence of diabetes in 
the years 2010–2014 in the total Polish population by 
using the data of the National Health Fund (NFZ). 
Material and methods 
The Polish system of healthcare is based on the 
insurance model. The public authorities ensure that all 
Polish citizens have equal access to healthcare services 
financed by public funds. The National Health Fund 
[22] is the health insurance institution performing 
the function of the payer. The National Health Fund 
finances health services which are granted to the 
insured people and reimburses medicines, foodstuffs 
and medical devices from resources from compulsory 
health insurance premiums.
Healthcare services are provided by the healthcare 
providers who concluded contracts about providing 
healthcare services with the National Health Fund. The 
healthcare providers providing (outpatient, as well as, 
hospital) healthcare services create and keep a regis-
ter of healthcare services in an electronic form which 
records all data characterizing each granted service. 
The data concerning the granted health service cover, 
among others, information characterizing the person 
who was provided with medical services (ie., PESEL — 
Personal Identification No.) and the disease entity code 
according to the ICD-10 classification, being the main 
reason for the provided service. These data are passed 
on to the National Health Fund [23].
The pharmacies are also obliged to collect and 
transfer data resulting from the filled prescriptions to 
the National Health Fund. The scope of the collected 
and transferred information containing data about the 
trade imedicines, foodstuffs for particular nutritional 
uses, medical devices subject to reimbursement, deter-
mined for each issued package or part of the package 
includes, among others, the PESEL of the patient who 
received the prescription and the code number of the 
medicine, foodstuff for particular nutritional uses or 
medical device (EAN, European Article Number) [24].
A retrospective analysis of the data base of the 
National Health Fund was carried out in the study. In 
the period from 1st January 2010 until 31st December 
2014 patients were distinguished according to the 
PESEL (personal identification) numbers:
 — for whom healthcare providers have disclosed the 
ICD-10 codes related to diabetes as the main cause 
of the medical intervention in the billing reports 
from services: E10 — insulin-dependent diabetes 
mellitus, E11 — noninsulin dependent diabetes 
mellitus, E12 — malnutrition-related diabetes, 
E13 — other undefined forms of diabetes, E14 — 
undefined diabetes;
 — who had got their prescriptions filled for any 
reimbursable hypoglycemic agent (insulins, oral 
antidiabetics) and/or for reimbursable glucose 
meter test strips.
The number of patients registered as diabetic 
patients and the number of patients who got their pre-
scriptions filled for hypoglycemic agents or test strips 
were assessed each year. The diabetes prevalence rate 
was calculated on the basis of the Polish demographic 
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data worked out by the Main Statistical Office [25]. The 
prevalence rate was defined as the percentage of peo-
ple recorded as patients with diabetes or a percentage 
of people who got their prescriptions filled for hypo-
glycemic agents or test strips in a given year in relation 
to the general population. The average percentage of 
people recorded as people with diabetes was also as-
sessed in the analyzed period and the prevalence rate 
per 100 thousand people was calculated in respective 
voivodeships.
Statistical methods
The analysis in the research was carried out on 
the basis of descriptive statistics: average values and 
standard deviations. Additionally, in order to compare 
the percentage of people recorded as patients with 
diabetes and those who bought pharmaceuticals asso-
ciated with diabetes or blood glucose meter test strips 
in relation to the general population in the consecutive 
years, c2 Pearson tests, Fisher’s exact probability test 
and the proportion test were carried out. All tests were 
verified on three materiality levels (5%, 1% and 0.1%).
Results 
Table 1 presents the number and percentage of pa-
tients recorded as subjects with diabetes according to the 
adequate ICD-10 codes and the number and percentage of 
patients who had the prescriptions filled for reimbursable 
hypoglycemic agents or reimbursable blood glucose meter 
test strips in the consecutive years. The average percentage 
of people recorded as patients with diabetes according to 
the ICD-10 codes in the years 2010–2014 amounted to 
4.47% (± 0.09%). The lower chart in figure 1 shows that 
this percentage has successively increased in the consecu-
tive years and each increase is statistically significant (the 
significance of the difference calculated for the percent-
ages of two successive years). However, the average 
percentage of people who bought medicines related to 
diabetes or test strips in the years 2010–2014 amounted 
to 5.88% (± 0.32%). In this case it can be noted that 
this percentage increased in 2011 and then significantly 
decreased in 2012. Significant increases were recorded 
again in the years 2013 and 2014 (Figure 1, upper line). 
Table 2 presents the average percentage of people 
recorded as patients with diabetes (according to the ad-
Figure 1. Percentage number of subjects with diagnosed diabetes (according to reported ICD-10 codes) and subjects who filled 
prescriptions for antidiabetic drugs and/or glucose meter strips in the years 2010–2014
Table 1. Number of patients with diagnosed diabetes (according to reported ICD-10 codes) and subjects who filled pre-
scriptions for anti-diabetic drugs and/or glucose meter strips in the years 2010–2014
Year Number of patients with diagnosed diabetes Number of patients who filled the prescriptions
2010, n (%) 1 678 187 (4.39%) 2 215 080 (5.80%)
2011, n (%) 1 697 277 (4.40%*) 2 433 433 (6.31%***)
2012, n (%) 1 702 129 (4.42%**) 2 109 263 (5.47%***)
2013, n (%) 1 731 341 (4.50%***) 2 213 815 (5.75%***)
2014, n (%) 1 775 745 (4.61%***) 2 339 889 (6.08%***)
*p < 0.05; **p < 0.01; ***p < 0.001
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Table 2. Mean (from the years 2010–2014), percentage of subjects with diagnosed diabetes (according to reported ICD-10 
codes) and prevalence index (per 100.000 inhabitants) in the particular regions (voivodeships)
Region (voivodeship) Percentage of people recorded  
as diabetes patients
Prevalence rate per 100  
thousand population
Lower silesia 4.7% (± 0.1%) 4697 (± 121.8)
Kuyavian-Pomeranian 4.6% (± 0.1%) 4574 (± 47.7)
Lublin 4.3% (± 0.1%) 4323 (± 67.6)
Lubusz 4.5% (± 0.1%) 4483 (± 103.2)
Łódź 5.0% (± 0.2%) 5028 (± 167.3)
Lesser Poland 4.0% (± 0.1%) 4014 (± 147.8)
Masovian 4.3% (± 0.1%) 4274 (± 95.3)
Opole 4.9% (± 0.1%) 4916 (± 72.0)
Subcarpathian 3.6% (± 0.2%) 3625 (± 154.9)
Podlaskie 3.9% (± 0.1%) 3870 (± 112.3)
Pomeranian 4.6% (± 0.1%) 4595 (± 57.3)
Silesian 5.5% (± 0.1%) 5458 (± 78.8)
Świętokrzyskie 4.6% (± 0.1%) 4605 (± 51.8)
Warmian-Masurian 3.5% (± 0.1%) 3459 (± 110.4)
Greater Poland 4.5% (± 0.2%) 4479 (± 184.6)
West Pomeranian 4.5% (± 0.1%) 4515 (± 83.0)
Poland 4.5% (± 0.1%) 4497 (± 94.7)
equate ICD-10 codes) and the average prevalence rate 
per 100 thousand residents in the analyzed period in 
respective voivodeships. The largest percentage of peo-
ple registered as patients with diabetes was recorded in 
Silesian Voivodeship and amounted to 5.5% (± 0.1%), 
the next consecutive voivodeship was Łódź Voivodeship 
— 5.0% (± 0,2%) and the third one was Opole Voivode-
ship — 4.9% (0.1%). The smallest percentage of people 
registered as patients with diabetes was recorded in 
Warmian-Masurian Voivodeship — 3.5% (± 0.1%) and 
Subcarpathian Voivodeship — 3.6% (± 0.2%).
Discussion
The average percentage of people recorded as 
patients with diabetes (according to adequate ICD-10 
codes) in Poland in the years 2010–2014 amounted to 
4.47% (± 0.09%), however, the average percentage 
of people who bought medicines related to diabetes 
or blood glucose meter test strips in the same period 
amounted to 5.88% (± 0.32%). It is noticeable that 
these percentages differ by 1.41%. This difference 
might result from the reporting system to the National 
Health Fund. The data transmitted by the healthcare 
providers to the National Health Fund concerning the 
granted health services include the code of its main 
cause (according to ICD-10) and codes of not more 
than three coexisting causes, essential for granting 
this service. Patients with diabetes usually have a few 
chronic diseases and diabetes may not have constituted 
the main cause of the granted service. The ICD-10 codes 
related to diabetes may thus not have been disclosed 
to the National Health Fund, but in spite of that pre-
scriptions were given to the patients for reimbursable 
hypoglycemic agents or test strips.
The consecutive potential cause of the afore-
mentioned difference (and in particular its increase in 
2013 and 2014) could be the emergence of a group 
of patients who are entitled to reimbursement for 
metformin, despite not having a diagnosed diabetes. 
Pursuant to the publication of the Minister of Health of 
24th April 2013 [26] the reimbursement for metformin 
was widened by applying a flat-rate charge. Since 2013 
metformin may be prescribed at a flat-rate under the 
following medical conditions: type 2 diabetes, predia-
betes, glucose intolerance, insulin resistance syndromes 
in other cases than diabetes, the polycystic ovary 
syndrome. However, despite the changes concerning 
reimbursement for metformin in 2013, the difference 
between the number of people who were reported to 
the National Health Fund as patients with diabetes and 
the number of patients who filled the prescriptions for 
the reimbursable hypoglycemic agents or test strips in 
the respective years has only increased slightly (vide 
Table 1).
Year 2011 is an exception, as the difference be-
tween these two variables is the biggest. This is perhaps 
the result of the announcement of the list of reimburs-
able medicines on 23rd December 2011 (with effect 
www.dk.viamedica.pl
Clinical Diabetology 2015, Vol. 4, No. 6
236
from 1st January 2012). This list does not include certain 
blood glucose meter test strips for marking glucose 
concentration, additionally the prices for the strips and 
the rapid-acting insulin analogs increased significantly. 
Suspecting a considerable increase in pharmaceutical 
drug expenditure, a lot of patients at the end of 2011 
purchased drugs and strips in order to hoard them. 
Using these reserves in the following year seems to 
be the cause of the reduction of the patients buying 
strips and pharmaceuticals related to diabetes in 2012. 
According to IDF data from 2014 prevalence of 
diabetes in Poland in the population at the age of 20–79 
amounted to 7.08% [3]. The average prevalence of 
diabetes indicated in our research (whether assessed on 
the basis of provided medical services or prescriptions) 
is slightly lower. This difference may result from differ-
ent criteria for inclusion. Prevalence of diabetes dem-
onstrated in various studies conducted in our country 
ranged from 2% for type 2 diabetes in the areas outside 
the large cities [11] to 22% among people over 65 years 
of age [20]. It is, however, difficult to compare these 
studies because, as previously mentioned, they were 
conducted in different cities or regions on the groups 
of patients in several age categories, they referred to 
different types and aspects of diabetes (in some cases 
diabetes was not the main subject of the research) and 
had a different methodology. The diabetes prevalence 
ranging from 4.47% to 5.88% assessed by authors of 
presented article is comparable to outcomes obtained 
in other European countries. The average diabetes 
prevalence rate for Europe in 2014 amounted to 
7.87%. Diabetes prevalence similar to Poland ranging 
from 4.5% to 6.0% was ascertained in the following 
countries: Kyrgyzstan, Uzbekistan, Tajikistan, Lithuania, 
Luxembourg and Great Britain. The highest prevalence 
of the disease was observed in Turkey (14.71%) and 
Portugal (13.09%) and the lowest in Azerbaijan (2.39%) 
and Armenia (2.78%) [3].
According to the data of the National Centre for 
Chronic Disease Prevention and Health Promotion 
(CDC) 21 million people suffered from diabetes in the 
USA in the same year, which is 6.7% of the population, 
additionally diabetes remained undiagnosed among 
8 million people [27]. However, the IDF data, as well 
as other American studies point to higher diabetes 
prevalence rates in this country [28].
Prevalence of diabetes in the Polish population 
differs among respective voivodeships. The largest 
percentage of people with diabetes was in Silesian 
Voivodeship and amounted to 5.5%, the second con-
secutive voivodeship was Łódź Voivodeship — 5.0% and 
Opole Voivodeship came in third — 4.9%. The smallest 
percentage of people with diabetes was noted in War-
mian-Masurian Voivodeship — 3.5% and Subcarpathian 
Voivodeship — 3.6%. It is difficult to explain where 
these differences come from, however the dispropor-
tions in the prevalence among respective voivodeships 
were also observed in the WOBASZ research [21]. The 
highest prevalence in this research was in the Greater 
Poland Voivodeship (9%), West-Pomeranian Voivode-
ship (8.9%) and Opole Voivodeship (8.3%) and the 
lowest for the Subcarpathian Voivodeship (5.3%) and 
the Lower-Silesian Voivodeship (5.8%).
Our research was limited due to the lack of division 
into age groups as well as its retrospective character. 
Additionally, the results presented above relate only 
to diabetes that had been diagnosed previously, how-
ever it should be borne in mind that diabetes among 
approximately 50% of patients remains undiagnosed 
(unknown diabetes). It is not possible to determine 
the scale of this problem in Poland on the basis of our 
research. This poses a question how many people suf-
fer from diabetes in our country but are not treated 
pharmacologically or do not perform self-monitoring 
(do not buy blood glucose meter test strips). Further as-
sessment is necessary in order to answer this question.
Conclusions
1. The average prevalence of diabetes in Poland in 
the years 2010–2014 amounted to 4.47% (the as-
sessment carried out on the basis of the number 
of people reported to the National Health Fund as 
diabetes patients according to the adequate ICD-10 
codes) or 5.88% (assessment on the basis of the 
number of people who filled the prescriptions for 
the reimbursable hypoglycemic agents or blood 
glucose meter test strips).
2. Prevalence of diabetes increases in Poland in the 
consecutive years.
3. Prevalence of diabetes differs among respective 
voivodeships.
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